Ashok Seth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ashok Seth has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
Vijay Kumar
Fortis Escorts Heart Institute, New Delhi, India
16 shared publicationsVishal Rastogi
Fortis Escorts Heart Institute, New Delhi, India
8 shared publicationsBabu Ezhumalai
7 shared publicationsUpendra Kaul
6 shared publications- Sengottuvelu Gunasekaran
Apollo Hospitals, Chennai, Tamil Nadu, India
5 shared publications - John Jose
Christian Medical College Vellore India
4 shared publications
Latest Publications
- 23 July 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (3) , 2005-2017
Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up
Background: Recently, Acurate neo2 (ACN2; Boston Scientific, US) and Sapien‐3 series (Edwards Lifesciences, US) were compared in the IDE trial failing to demonstrate non‐inferiority of ACN2. The Myval series (MyV), an alternative balloon‐expandable device, demonstrated non‐inferiority compared to Sapien‐3 and Evolut (Medtronic, US) in the LANDMARK trial. However, no direct comparison exists between ACN2 and MyV. Aims: We aimed to compare mid‐term clinical and hemodynamic outcomes of the ACN2 and MyV transcatheter heart valves. Methods: This multicenter retrospective analysis included patients implanted with ACN2 and MyV series devices. The primary objective was to assess 1‐year mortality and stroke rates. Secondary outcomes included technical success, mortality, stroke, residual aortic regurgitation (AR), mean aortic gradients, and new permanent pacemaker implantation (PPI) rates up to 4 years. A matched comparison adjusting for clinical and anatomical characteristics was performed and echocardiograms were centrally analyzed. Results: A total of 545 patients (ACN2: 144; MyV: 401) from nine institutions were included. Matched technical success rates were 87.6% and 94.4%, p = 0.180 (90.3% for ACN2 and 97% for MyV; p < 0.001 in unmatched). In‐hospital matched PPI rates were 10.1% for ACN2 and 9% for MyV. At 4 years, matched residual ≥ moderate AR rates were similar (ACN2: 15.8% vs. MyV: 21.1%, p = 0.706), though ACN2 showed better mean aortic gradients (9.2 ± 4.2 vs. 13.1 ± 5.4, p = 0.001) and effective orifice area. Unmatched mortality + stroke rates were comparable but lower for ACN2 after matching (3.4% vs. 15.7%, p = 0.005). Importantly, cardiovascular mortality (3.4% for ACN2 and 5.6% for MyV, p = 0.720) and valve‐related deaths were comparable. Conclusion: ACN2 showed superior long‐term hemodynamics and lower matched 4‐year mortality and stroke rates, though cardiovascular mortality and valve‐related deaths were comparable.
- 23 July 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (3) , 2005-2017
Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up
Background: Recently, Acurate neo2 (ACN2; Boston Scientific, US) and Sapien‐3 series (Edwards Lifesciences, US) were compared in the IDE trial failing to demonstrate non‐inferiority of ACN2. The Myval series (MyV), an alternative balloon‐expandable device, demonstrated non‐inferiority compared to Sapien‐3 and Evolut (Medtronic, US) in the LANDMARK trial. However, no direct comparison exists between ACN2 and MyV. Aims: We aimed to compare mid‐term clinical and hemodynamic outcomes of the ACN2 and MyV transcatheter heart valves. Methods: This multicenter retrospective analysis included patients implanted with ACN2 and MyV series devices. The primary objective was to assess 1‐year mortality and stroke rates. Secondary outcomes included technical success, mortality, stroke, residual aortic regurgitation (AR), mean aortic gradients, and new permanent pacemaker implantation (PPI) rates up to 4 years. A matched comparison adjusting for clinical and anatomical characteristics was performed and echocardiograms were centrally analyzed. Results: A total of 545 patients (ACN2: 144; MyV: 401) from nine institutions were included. Matched technical success rates were 87.6% and 94.4%, p = 0.180 (90.3% for ACN2 and 97% for MyV; p < 0.001 in unmatched). In‐hospital matched PPI rates were 10.1% for ACN2 and 9% for MyV. At 4 years, matched residual ≥ moderate AR rates were similar (ACN2: 15.8% vs. MyV: 21.1%, p = 0.706), though ACN2 showed better mean aortic gradients (9.2 ± 4.2 vs. 13.1 ± 5.4, p = 0.001) and effective orifice area. Unmatched mortality + stroke rates were comparable but lower for ACN2 after matching (3.4% vs. 15.7%, p = 0.005). Importantly, cardiovascular mortality (3.4% for ACN2 and 5.6% for MyV, p = 0.720) and valve‐related deaths were comparable. Conclusion: ACN2 showed superior long‐term hemodynamics and lower matched 4‐year mortality and stroke rates, though cardiovascular mortality and valve‐related deaths were comparable.
- Open Access
- 1 November 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Asian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exists a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomical variations, disparity in healthcare resources and infrastructure and the lack of consensus on the optimal management of aortic stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons and imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral.’ The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis.
- 1 November 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Open AccessAsian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exists a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomical variations, disparity in healthcare resources and infrastructure and the lack of consensus on the optimal management of aortic stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons and imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral.’ The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis.
- Open Access
- 1 October 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Asian Pacific Society of Cardiology Consensus Statements on the Use of Percutaneous Coronary Intervention on Stenosis of the Left Main Coronary Artery
Stenosis of the left main coronary artery (LM stenosis) is associated with significant mortality and morbidity due to the large area of affected myocardium. Evidence on the use of percutaneous coronary intervention (PCI) for the treatment of LM stenosis is growing. However, the role of Western guidelines on patients in the Asian-Pacific region is unclear due to anatomical variations, substantial heterogeneity in healthcare resources and infrastructure, and the lack of consensus on the optimal management of LM stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group developed consensus recommendations on the use of PCI in the management of LM stenosis in the Asia-Pacific region. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral’. The resulting 12 statements provide guidance for clinical practitioners in the region on the use of PCI in the treatment of patients with LM stenosis.
- 1 October 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Open AccessAsian Pacific Society of Cardiology Consensus Statements on the Use of Percutaneous Coronary Intervention on Stenosis of the Left Main Coronary Artery
Stenosis of the left main coronary artery (LM stenosis) is associated with significant mortality and morbidity due to the large area of affected myocardium. Evidence on the use of percutaneous coronary intervention (PCI) for the treatment of LM stenosis is growing. However, the role of Western guidelines on patients in the Asian-Pacific region is unclear due to anatomical variations, substantial heterogeneity in healthcare resources and infrastructure, and the lack of consensus on the optimal management of LM stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group developed consensus recommendations on the use of PCI in the management of LM stenosis in the Asia-Pacific region. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral’. The resulting 12 statements provide guidance for clinical practitioners in the region on the use of PCI in the treatment of patients with LM stenosis.
- Open Access
- 3 September 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (4) , 688-696
Safety, efficacy, and optical coherence tomography insights into intravascular lithotripsy for the modification of non‐eruptive calcified nodules: A prospective observational study
Background: Non‐eruptive calcium nodules (CNs) are commonly seen in heavily calcified coronary artery disease. They are the most difficult subset for modification, and may result in stent damage, malapposition and under‐expansion. There are only limited options available for non‐eruptive CN modification. Intravascular lithotripsy (IVL) is being explored as a potentially safe and effective modality in these lesions.Aims: This study aimed to investigate the safety and efficacy of the use of IVL for the modification of non‐eruptive CNs. The study also explored the OCT features of calcium nodule modification by IVL.Methods: This is a single‐center, prospective, observational study in which patients with angiographic heavy calcification and non‐eruptive CN on OCT and undergoing PCI were enrolled. The primary safety endpoint was freedom from perforation, no‐reflow/slow flow, flow‐limiting dissection after IVL therapy, and major adverse cardiac events (MACE) during hospitalization and at 30 days. MACE was defined as a composite of cardiac death, myocardial infarction (MI), and ischemia‐driven target lesion revascularization (TLR). The primary efficacy endpoint was procedural success, defined as residual diameter stenosis of 80%) at the CN was achieved in 85.71% of patients. All patients remained free from MACE during hospitalization and at the 30‐day follow‐up. At 1‐year follow‐up, all‐cause death had occurred in 3 (14.3%) patients.Conclusions: This single‐arm study demonstrated the safety, efficacy, and utility of the IVL in a subset of patients with non‐eruptive calcified nodules. In this study, minimal procedural complications, excellent lesion modifications, and favorable 30‐day and 1‐year outcomes were observed.
- 3 September 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (4) , 688-696
Open AccessSafety, efficacy, and optical coherence tomography insights into intravascular lithotripsy for the modification of non‐eruptive calcified nodules: A prospective observational study
Background: Non‐eruptive calcium nodules (CNs) are commonly seen in heavily calcified coronary artery disease. They are the most difficult subset for modification, and may result in stent damage, malapposition and under‐expansion. There are only limited options available for non‐eruptive CN modification. Intravascular lithotripsy (IVL) is being explored as a potentially safe and effective modality in these lesions.Aims: This study aimed to investigate the safety and efficacy of the use of IVL for the modification of non‐eruptive CNs. The study also explored the OCT features of calcium nodule modification by IVL.Methods: This is a single‐center, prospective, observational study in which patients with angiographic heavy calcification and non‐eruptive CN on OCT and undergoing PCI were enrolled. The primary safety endpoint was freedom from perforation, no‐reflow/slow flow, flow‐limiting dissection after IVL therapy, and major adverse cardiac events (MACE) during hospitalization and at 30 days. MACE was defined as a composite of cardiac death, myocardial infarction (MI), and ischemia‐driven target lesion revascularization (TLR). The primary efficacy endpoint was procedural success, defined as residual diameter stenosis of 80%) at the CN was achieved in 85.71% of patients. All patients remained free from MACE during hospitalization and at the 30‐day follow‐up. At 1‐year follow‐up, all‐cause death had occurred in 3 (14.3%) patients.Conclusions: This single‐arm study demonstrated the safety, efficacy, and utility of the IVL in a subset of patients with non‐eruptive calcified nodules. In this study, minimal procedural complications, excellent lesion modifications, and favorable 30‐day and 1‐year outcomes were observed.
- Open Access
- 24 April 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Acute MI-Cardiogenic Shock and Endorsed by the Asian Pacific Society of Interventional Cardiology
In the Asia-Pacific region, acute MI (AMI) is associated with a high rate of cardiogenic shock (CS), which increases the risk of mortality several-fold. The management of AMI-CS in the region is heterogeneous and lacks consensus. Hence, an Asian Pacific Society of Cardiology working group developed consensus recommendations on the management of AMI-CS in the Asia-Pacific region. The Asian Pacific Society of Cardiology expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were ‘agree’ or ‘neutral.’ The resulting statements, which have been endorsed by the Asian Pacific Society of Interventional Cardiology and affirmed by the Society for Cardiovascular Angiography and Interventions, provide guidance on the diagnosis, assessment and treatment of patients with AMI-CS among clinical practitioners in the region.
- 24 April 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Open AccessAsian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Acute MI-Cardiogenic Shock and Endorsed by the Asian Pacific Society of Interventional Cardiology
In the Asia-Pacific region, acute MI (AMI) is associated with a high rate of cardiogenic shock (CS), which increases the risk of mortality several-fold. The management of AMI-CS in the region is heterogeneous and lacks consensus. Hence, an Asian Pacific Society of Cardiology working group developed consensus recommendations on the management of AMI-CS in the Asia-Pacific region. The Asian Pacific Society of Cardiology expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were ‘agree’ or ‘neutral.’ The resulting statements, which have been endorsed by the Asian Pacific Society of Interventional Cardiology and affirmed by the Society for Cardiovascular Angiography and Interventions, provide guidance on the diagnosis, assessment and treatment of patients with AMI-CS among clinical practitioners in the region.
- Open Access
- 10 April 2023
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 18, e12
Myval: A Novel Transcatheter Heart Valve for the Treatment of Severe Aortic Stenosis
Transcatheter aortic valve implantation (TAVI) performed using femoral arterial access is now a guideline recommended treatment for severe calcific aortic stenosis (AS) in elderly patients. Technological advancements and procedural refinements have focused on making TAVI simpler, safer, more effective and durable. Myval (Meril Lifesciences) is a new generation balloon-expandable transcatheter heart valve (THV) developed in India that possesses novel features to improve deliverability and aid precise deployment. Following the first-in-human study, Myval was approved in India for commercial implantation in October 2018 and was subsequently given a CE mark in April 2019. This article reviews the science, technology and up-to-date clinical evidence for the Myval THV.
- 10 April 2023
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 18, e12
Open AccessMyval: A Novel Transcatheter Heart Valve for the Treatment of Severe Aortic Stenosis
Transcatheter aortic valve implantation (TAVI) performed using femoral arterial access is now a guideline recommended treatment for severe calcific aortic stenosis (AS) in elderly patients. Technological advancements and procedural refinements have focused on making TAVI simpler, safer, more effective and durable. Myval (Meril Lifesciences) is a new generation balloon-expandable transcatheter heart valve (THV) developed in India that possesses novel features to improve deliverability and aid precise deployment. Following the first-in-human study, Myval was approved in India for commercial implantation in October 2018 and was subsequently given a CE mark in April 2019. This article reviews the science, technology and up-to-date clinical evidence for the Myval THV.
- Open Access
- 5 April 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 382, 68-75
Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication
- 5 April 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 382, 68-75
Open AccessAngiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication
- Open Access
- 20 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2398
One-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm2, moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes.
- 20 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2398
Open AccessOne-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm2, moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes.
- 9 March 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (5) , 963-964
Cusp overlap technique for self‐expanding valves: Refining technique defining outcomes
Key Points: Cusp overlap (COV) technique for Transcatheter Aortic Valve Implantation (TAVI) with self‐expanding valves (SEV) has been proposed to enable accurate and high placement of valves to decrease permanent pacemaker implantation (PPI). Metanalysis of published experience with COV technique confirms decrease in PPI rates without compromising on safety. COV technique could be considered the technique of choice for implantation of SEV.
- 9 March 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (5) , 963-964
Cusp overlap technique for self‐expanding valves: Refining technique defining outcomes
Key Points: Cusp overlap (COV) technique for Transcatheter Aortic Valve Implantation (TAVI) with self‐expanding valves (SEV) has been proposed to enable accurate and high placement of valves to decrease permanent pacemaker implantation (PPI). Metanalysis of published experience with COV technique confirms decrease in PPI rates without compromising on safety. COV technique could be considered the technique of choice for implantation of SEV.
- 29 November 2022
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 100 (6) , 1148-1149
Percutaneous Coronary Intervention of bifurcation lesions: The proof is in the pudding!
Key Points: Provisional stenting strategy is the most common technique for treatment of bifurcation lesion in the ‘real world' patients undergoing percutaneous coronary intervention. The technical success appears to be lower in provisional stent strategy compared to upfront two stent strategy due to worsening of the ostial side branch lesions after main branch stenting; following wire recrossing and side branch dilation/stent implantation stenting leads to equivalent procedural success and in hospital outcomes. Side branch access after main branch stenting is technically challenging and an algorithmic approach helps to achieve procedural success.
- 29 November 2022
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 100 (6) , 1148-1149
Percutaneous Coronary Intervention of bifurcation lesions: The proof is in the pudding!
Key Points: Provisional stenting strategy is the most common technique for treatment of bifurcation lesion in the ‘real world' patients undergoing percutaneous coronary intervention. The technical success appears to be lower in provisional stent strategy compared to upfront two stent strategy due to worsening of the ostial side branch lesions after main branch stenting; following wire recrossing and side branch dilation/stent implantation stenting leads to equivalent procedural success and in hospital outcomes. Side branch access after main branch stenting is technically challenging and an algorithmic approach helps to achieve procedural success.